For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A Multicenter Phase 2, Open Label Study Of Intratumoral CMP-001 In Combination With Intravenous Pembrolizumab In Subjects With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
To determine the safety and efficacy of the study drug, CMP-001, when given in combination with pembrolizumab.
DiagnosisPatient has recurrent or metastatic squamous cell carcinoma of the head and neck.
Incurable Recurrent/Metastatic HNSCC.
No prior systemic therapy in recurrent/metastatic setting.
One lesion amiable to repeated IT injection.
Ineligible if PD within 3 months of curative therapy.
No prior immunotherapy.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
CMP-001 + Pembrolizumab may be given as an injection into patient’s skin or tumor.
For more information, visit ClinicalTrials.gov